Skip to content
Screener

Surgery Partners, Inc. SGRY Cash & Equivalents

Cash & Equivalents at other companies

Tenet Healthcare logo
Tenet HealthcareTHC
$2.17B-17.3%
UnitedHealth Group logo
UnitedHealth GroupUNH
$28B-8.8%
Encompass Health Corporation logo
Encompass Health CorporationEHC
$163.4M+33.1%
HCA Healthcare logo
HCA HealthcareHCA
$1.01B+7.9%
ARD
Ardent Health PartnersARDT
$609.69M+23.2%
National Healthcare logo
National HealthcareNHC
$39.21M-64.7%

Other financials

Income statement

See full
Revenue$810.9M+4.5%
Operating income$65.8M+6.3%
Net income-$35.9M+4.8%
EPS (diluted)-$0.28+6.7%

Balance sheet

See full
Total debt$5.1B+4.6%
Total equity$1.7B-3.0%
Total assets$8.0B+1.2%

Cash flow

See full
Operating cash flow$11.7M+95.0%
CapEx$16.0M-29.5%
Free cash flow-$4.3M+74.3%

Valuation

See full
Market cap$1.95B-32.1%
Enterprise value$6.82B-9.2%
P/S0.6×-0.3×

Profitability

See full
Gross margin23.1%—
Operating margin11.8%+1.2pp
Net margin-2.3%-0.9pp
FCF margin6.2%+0.8pp

Returns & leverage

See full
Return on equity-4.4%-1.6pp
Debt / equity3×+0.2×
Current ratio1.9×0.0×

Where this comes from

Reported directly by Surgery Partners, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Surgery Partners, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001638833-26-000046
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Payments of debt issuance costs(0.4)—
Distributions to non-controlling interest holders(58.0)(62.3)
Proceeds related to ownership transactions with non-controlling interest holders0.51.7
Other financing activities0.4(3.5)
Net cash provided by (used in) financing activities(55.9)30.2
Net increase (decrease) in cash and cash equivalents(57.6)(40.2)
Cash and cash equivalents at beginning of period239.9269.5
Cash and cash equivalents at end of period$182.3$229.3

Item 1. Financial Statements

FAQ

What is Surgery Partners, Inc.'s cash & equivalents?
Surgery Partners, Inc. (SGRY) reported cash & equivalents of $182.3M in Q1 2026.
How has Surgery Partners, Inc.'s cash & equivalents changed year-over-year?
Surgery Partners, Inc.'s cash & equivalents decreased by 20.5% year-over-year, from $229.3M to $182.3M.
What is the long-term trend for Surgery Partners, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Surgery Partners, Inc.'s cash & equivalents has grown at a -5.5% compound annual growth rate (CAGR), from $318.2M to $239.9M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Surgery Partners, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude